

23 **Zhi Liu**

24 Institution: Department of Orthopaedics, Xiangya Hospital, Central South University,

25 Changsha, 410008, Hunan, China.

26 E-mail address: liuzhi990107@163.com

27 **Peng Chen**

28 Institution: Department of Orthopaedics, Xiangya Hospital, Central South University,

29 Changsha, 410008, Hunan, China.

30 E-mail address: chenpeng150@csu.edu.cn

31 **Tongtong Xie**

32 Institution: College of Electrical and Information Engineering, Hunan University, Changsha,

33 410008, Hunan, China.

34 E-mail: xietongtong@hnu.edu.cn

35 **Li Meng**

36 Institution: Department of Radiology, Xiangya Hospital, Central South University,

37 Changsha, 410008, Hunan, China.

38 E-mail: mengli96130@csu.edu.cn

39 **Shushan Zhao (Corresponding Author) ***

40 Institution: Department of Orthopaedics, Xiangya Hospital, Central South University,

41 Changsha, 410008, Hunan, China.

42 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South

43 University, Changsha, Hunan 410008, China.

44 E-mail: shushanzhao@csu.edu.cn

45 **Haitao Long (Corresponding Author) ***

46 Institution: Department of Orthopaedics, Xiangya Hospital, Central South University,

47 Changsha, 410008, Hunan, China.

48 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South

49 University, Changsha, Hunan 410008, China.

50 E-mail: doclong2008@aliyun.com

51

52 **Abstract**

53 **Objectives:** Observational studies have shown the association between knee osteoarthritis (KOA)
54 and neurological disorders with alterations in brain imaging-derived phenotypes (BIDPs). This
55 study aimed at investigating whether alterations in brain structure are correlated with the occurrence
56 of KOA.

57 **Methods:** Based on the summary data from two large scale genome-wide association studies
58 (GWASs), we performed a bidirectional two-sample Mendelian randomization (MR) analysis using
59 single-nucleotide polymorphisms (SNPs) as instrumental variables (IVs) to determine the potential
60 causal relationships between KOA and BIDPs.

61 **Results:** We identified the genetic correlations of 152 BIDPs with KOA using linkage
62 disequilibrium score regression. MR analysis revealed that increased volume but decreased
63 intensity-contrast of bilateral nucleus accumbens (NAc), as well as increased left paracentral area
64 was positively causally associated with KOA risk. For the IDPs of structural connectivity, we
65 identified causal associations between multiple increased DTI parameter indicators of corticospinal
66 tract (CST) and KOA. Inversely, KOA was positively correlated with the thickness and intensity-
67 contrast of the rostral anterior cingulate, as well as the intensity-contrast of caudal anterior cingulate,
68 insula cortex, and the grey matter volume of pallidum.

69 **Conclusion:** Our study supported bidirectional causal associations between KOA and BIDPs,
70 which may provide new insights into the interaction of KOA with structural alterations in the
71 nervous system.

72 **Keywords:** Mendelian randomization, brain imaging-derived phenotypes, knee osteoarthritis, causal

73 association.

74 **1. Introduction**

75 Osteoarthritis (OA) is the most common musculoskeletal disorder around the world, it is
76 characterized by articular cartilage degeneration, osteophyte formation, and asymmetric joint spaces
77 narrowing, leading to pain and disability[1]. It has been recently estimated that there is an overall
78 prevalence of about 300 million for OA, of which 263 million had knee osteoarthritis (KOA)[2].
79 With prolonged life expectancy and population aging, the prevalence of KOA is predicted to
80 dramatically increase in the future. Epidemiologic studies have shown that the most common risk
81 factors for KOA include previous joint injuries, older age, obesity, female gender, and anatomical
82 abnormalities of the joints[3].

83 It has been found that many neurological disorders such as major depressive disorder (MDD)[4,
84 5], Alzheimer's disease (AD)[6, 7], Parkinson's disease (PD)[8], and cerebrovascular dysfunction
85 diseases[9] are closely related to OA and may be comorbidities or risk factors for it. Neuroimaging
86 techniques have been utilized in recent years for the non-invasive detection of central and peripheral
87 nervous system degeneration so as to monitor disease progression and prognosis, and it has also
88 been applied to investigate brain structure, function and metabolism[10, 11]. It is also worth noting
89 that these disorders usually have neurological degeneration to certain extent. Most magnetic
90 resonance-based structural imaging studies suggested that the degree and rate of atrophy in medial
91 temporal structures, such as the hippocampus, can be recognized as diagnostic and progression
92 markers or AD[12]. Another recent structural network study using diffusion tensor imaging (DTI)
93 revealed that lower fractional anisotropy (FA) values of superior longitudinal fasciculus, prefrontal
94 cortex, and parietal lobe in left hemisphere among patients with MDD compared to health
95 controls[13]. However, there are no studies investigating whether brain structure alterations are

96 associated with the occurrence of KOA.

97 Mendelian randomization (MR) utilizes genetic variants, such as single-nucleotide
98 polymorphisms (SNPs), as instrumental variables (IVs) to determine the potential associations
99 between exposures and disorders, and it circumvents the bias caused by confounding factors in
100 traditional observational studies[14]. With the development of genome-wide association studies
101 (GWAS), a large number of public databases are now available for MR studies to assess potential
102 causal associations between OA and other diseases[15-17]. Here we used SNPs strongly associated
103 with brain imaging-derived phenotypes (BIDPs) and KOA as IVs. We performed a bidirectional
104 two-sample MR analysis to investigate the association between brain structures and KOA risk.

105 **2. Materials and Methods**

106 **2.1 Brain imaging-derived phenotypes (BIDPs) data**

107 A recent GWAS of brain imaging traits was performed on 33,224 individuals of European
108 ancestry (aged between 40 and 80 years) based on data from the UK Biobank Error! Reference source not
109 found. Full summary GWAS statistics for the BIDPs are available from the Oxford Brain Imaging
110 Genetics (BIG40) (<https://open.win.ox.ac.uk/ukbiobank/big40>).

111 The selected BIDPs are divided into two categories: brain structure (structural MRI) and brain
112 structural connectivity (diffusion MRI, dMRI). The original IDPs for brain structure are T1- or T2-
113 weighted structural images, which are subsequently processed by different algorithms to generate
114 the final traits. The structural brain connectivity IDPs are initially determined by dMRI, which
115 measures the diffusion of water molecules and allows for the indirect mapping of the axon
116 connectivity in the human brain. Details procedures of imaging acquisition and processing of brain

117 MRI scans can be found in previous studies. Overall, we extracted brain structures including 1,451
118 global and regional anatomical subtypes, including volume, subcortical thickness and superficial
119 area, regional and tissue intensity, cortical gray-white contrast, as well as 675 brain structural
120 connections, including long-range structural connectivity and local microstructure (**Supplementary**
121 **Table 1**).

122 **2.2 Knee osteoarthritis (KOA) data**

123 Summary statistics for KOA were obtained from Arthritis Research UK Osteoarthritis Genetics
124 (arcOGEN) Consortium cohorts of European descent (<http://www.arcogen.org.uk/>), which included
125 11,655 individuals (646 cases and 11,009 controls)[18]. Osteoarthritis cases were identified on the
126 basis of clinical evidence of disease to a level requiring joint replacement or radiographic evidence
127 of disease (Kellgren–Lawrence grade ≥ 2).

128 **2.3 Linkage disequilibrium score regression (LDSC) analysis**

129 LD score regression is a reliable and efficient method to estimate the SNP heritability for
130 complex traits and diseases GWAS summary-level results, and has recently been used to determine
131 whether different traits have overlapping genetic backgrounds[19]. LDSC regression was first used
132 to assess the correlation between BIDPs and KOA, which can be inferred from the regression slope.
133 Variants were excluded if the following criteria were met: missing value, missing in Hapmap3,
134 INFO score ≤ 0.9 , minor allele frequency (MAF) ≤ 0.01 , non-SNPs or rs number duplicates.

135 **2.4 Instrumental variable selection**

136 The genetic variants utilized as IVs for MR should be strongly related to the exposure,
137 independent from any confounding factors, and independent from any pathway associated with the

138 outcome, except for the exposure pathway. In our MR analysis, we initially extracted IVs based on
139 the genome-wide significance threshold ($p < 5 \times 10^{-8}$), followed by calculating the F statistics of
140 each SNP to exclude weak IVs with F statistics < 10 . We then ensured independence among IVs
141 for each exposure by conducting an LD test on each SNP identified as an IV based on individuals
142 with European ancestry from the 1000 Genomes Project with $r^2 < 0.001$ and a window size of 10,000
143 kb. Finally, in case the target SNPs were not found in the outcome GWAS, we used SNPs with high
144 LD ($r^2 > 0.8$) to substitute.

145 **2.5 Mendelian randomization**

146 To analyze the causal association between BIDPs and KOA, we utilized multiple
147 complementary methods, including inverse variance weighted (IVW), MR-Egger, weighted median,
148 simple mode, weighted mode, and Wald ratio methods. The IVW model was used as the major
149 primary statistical method, and the Wald ratio method was used when a genetic variant contained
150 only one genetically related SNP. We assessed the presence of horizontal pleiotropy by using
151 Cochran's Q statistic to test for heterogeneity among IVs, with $p < 0.05$ indicating heterogeneity. If
152 heterogeneity was present, we used the random-effects model for subsequent analyses; otherwise,
153 we used the fixed-effects model. Leave-one-out cross-validation was performed to evaluate the
154 stability of the MR results through sequential exclusion of each IV. In addition, we conducted MR-
155 Egger analysis to identify directional pleiotropy. Funnel plot asymmetry indicated the presence of
156 horizontal pleiotropy. In the current study, we focused on those positive MR analysis results with
157 the number of SNPs greater than or equal to three.

158 **2.6 Statistical Analyses**

159 All statistical analyses were performed using the "TwoSampleMR" and "MR-PRESSO"

160 packages of R software (version 3.3). All estimates are reported as two-tailed p values with the
161 threshold of significance at 0.05.

162 **3. Results**

163 **3.1 Linkage Disequilibrium Score Regression**

164 We first examined the genetic association of GWAS datasets of 2,126 BIDPs with KOA using
165 LDSC. A total of 152 BIDPs (53 IDPs of brain structure and 99 IDPs of structural connectivity,
166 respectively) showed significant correlations with the risk of KOA (**Supplementary Table 2**).

167 **3.2 Causal effect of BIDPs on KOA**

168 F -statistic is used to assess the strength of the association between instrumental variables and
169 exposure factors. All F -statistics are greater than 10 (range:29.73-1081.32, with an average value
170 of 51.89), indicating a relatively low likelihood of weak instrument bias for the instrumental
171 variables (**Supplementary Table 3**).

172 In the current MR analysis, a total of 60 BIDPs were identified to be causally associated with
173 the risk of KOA (**Table 1**). Among the brain structural IDPs relevant to the nucleus accumbens
174 (NAc), the increased volume in both left ($\beta = 0.4893, p = 0.0434$) and right ($\beta = 0.6877, p = 0.029$)
175 hemisphere was found to be positively causally associated with KOA. However, the increased
176 intensity contrast of NAc in both hemispheres had a negative causal association with KOA (left: β
177 = -0.1829, $p = 0.046$; right: $\beta = -0.1862, p = 0.0322$). In addition, the increased paracentral area in
178 the left hemisphere measured by Desikan ($\beta = 0.7444, p = 0.0248$) and DKAtlas ($\beta = 0.7398, p =$
179 0.0266) algorithms, the left BA4a area ($\beta = 0.7274, p = 0.029$), the total white matter volume ($\beta =$
180 0.3356, $p = 0.0386$), the bilateral gray matter volume of putamen (left: $\beta = 0.2259, p = 0.009$; right:

181 $\beta = 0.1957, p = 0.0293$) and cerebellum_crus_I (left: $\beta = 0.2991, p = 0.012$; right: $\beta = 0.2984, p =$
182 0.0343), and the bilateral cuneus intensity contrast (left: $\beta = 0.2257, p = 0.046$; right: $\beta = 0.2807, p$
183 $= 0.0084$) were positively correlated with KOA. We also observed significant causal effects of the
184 decreased left circular sulcus volume ($\beta = -1.0172, p = 0.0173$), right superior temporal area ($\beta = -$
185 $0.5876, p = 0.0363$), left inferior temporal thickness based on Desikan ($\beta = -0.695, p = 0.0121$) and
186 *aparc-a2009s* ($\beta = -0.6405, p = 0.024$) parcellation, as well as right amygdala intensity contrast (β
187 $= -0.6031, p = 0.0464$) on KOA risk (**Table 1**).

188 For the IDPs of structural connectivity derived from dMRI data, we found significant causal
189 relationships between parameters on FA (fractional anisotropy) of axonal connections such as the
190 corticospinal tract (CST), the pontine crossing tract (PCT), the superior thalamic radiation, the
191 superior longitudinal fasciculus, the fronto-occipital fasciculus, as well as of local microstructures
192 such as the anterior limb of internal capsule and KOA risk (**Table 1**). Notably, our results supported
193 causal associations between several decreased DTI parameter indicators (including Mean MD,
194 Mean L1/L2/L3, and Mean ISOVF) of CST/PCT and KOA. The detailed MR estimates of the
195 different methods were presented in **Supplementary Table 4**. No directional pleiotropy was found
196 in the MR-Egger regression (**Supplementary Table 5**). The detailed forest plots, scatter plots,
197 funnel plots, and leave-one-out analysis plots for each analysis were presented in **Supplementary**
198 **Figure 1–50**.

199 **3.3 Causal effect of KOA on BIDPs**

200 We further explored the reverse causal effect of KOA on BIDPs using the KOA-related SNPs
201 as IVs, with an F -statistic > 10 (range: 22.51–28.12, with an average value of 24.91). We found that

202 increased risk of KOA could reduce the thickness of right caudomedial frontal lobe and the area of
203 left parahippocampal gyrus under both Desikan and DKAtlas parcellation (**Table 2**). However,
204 KOA was positively correlated with the thickness and intensity-contrast of the left rostral anterior
205 cingulate, as well as the intensity-contrast of caudal anterior cingulate (left: $\beta = 0.071, p = 0.017$;
206 right: $\beta = 0.075, p = 0.011$), the intensity-contrast of insula cortex in right hemisphere ($\beta = 0.072, p$
207 $= 0.016$), and the grey matter volume of in both left ($\beta = 0.1, p = 0.0001$) and right ($\beta = 0.079, p =$
208 0.006) pallidum. In addition, KOA could contribute to decreased Mean ISOVF in medial thalamic
209 (left: $\beta = -0.063, p = 0.036$; right: $\beta = -0.064, p = 0.033$) (**Table 2**).

210 **4. Discussion**

211 To the best of our knowledge, this is the first two-sample MR study to investigate causal
212 relationships between KOA and BIDPs. Our study supported bidirectional causal associations
213 between KOA and BIDPs, which may provide new insights into the interaction of KOA with
214 structural alterations in the nervous system.

215 Although OA and neurological disorders belong to two distinct medical categories, the close
216 association between them has been well documented[5, 6]. A recent MR study further assessed
217 causal relationships between osteoarthritis and central nerve system dysfunction in the elderly,
218 which suggested that there was a positive causal effect of OA on PD, but not on AD nor ischemic
219 stroke[20]. Neuroimaging techniques have been utilized in monitoring the progression and
220 prognosis of neurological diseases. Owing to the increasing availability of MRI-based GWAS,
221 structural imaging studies have revealed alterations in BIDPs in neurological disorders. For example,
222 the causal AD-associations for the left hippocampus and right inferior temporal cortex volumes have
223 been identified by utilizing brain MRI database from the Alzheimer's Disease Neuroimaging

224 Initiative and the UK Biobank[21]. However, the causal relationship between BIDP alterations and
225 KOA is still unclear.

226 Our findings supported that increased area of the paracentral lobule (PCL) could reduce the risk
227 of KOA. The PCL is on the medial surface of the cerebral hemisphere and is the continuation of the
228 precentral and postcentral gyri. In the human brain, motor control and somatosensory
229 representations of different parts of the body are ordered respectively along the entire range of the
230 precentral and postcentral gyrus (generally categorized into five sections: toes/legs, arms/hands,
231 blinking, mouth, and tongue)[22, 23]. Interestingly, the PCL controls motor and sensory
232 innervations of the contralateral lower extremity, including the knee. Pain is an important
233 somatosensation and a major symptom of OA, especially, in KOA where pain is recognized as
234 typically changing from intermittent weight-bearing pain to chronic pain[24]. Several studies have
235 reported the association between chronic pain and reduced gray matter in areas associated with pain
236 processing and modulation, such as the dorsolateral prefrontal cortex, thalamus, dorsolateral pons,
237 and somatosensory cortex[25-27]. Another study also reported a significant reduction in gray matter
238 volume in the left precentral gyrus in patients with KOA relative to healthy controls[28]. Here we
239 identified that alterations in the area of PCL as a cause, rather than a consequence, of KOA.
240 Moreover, we found that increased BA4a area in the left hemisphere was also a protective factor for
241 KOA. BA4 belongs to the anterior two-thirds of the PCL (medial surface of the precentral gyrus),
242 where the ungranulated cortex reflects the primary motor cortex in the PCL for the contralateral leg
243 and foot muscles, reinforcing its possible role in the pathogenesis of OA[29].

244 The nucleus accumbens (NAc) is a subcortical brain structure located in the ventral striatum. It
245 is often known as the pleasure center and is closely associated with behaviors such as reward,

246 motivation, and learning[30]. Its imbalance is commonly associated with many mental and
247 neurological disorders such as depression, obsessive-compulsive disorder, anxiety, and substance
248 abuse[31]. In recent years, however, the NAc has been shown to play a role in acute and chronic
249 pain modulation[32, 33], and even to be effective in pain relief through deep brain stimulation of
250 the human NAc[34]. Although the current study found a causal link between increased volume but
251 decreased intensity-contrast of NAc and KOA risk, further studies are still needed to determine
252 whether the altered neuroimaging in this region is associated with changes in the size, number, and
253 function of neurons or glial cells.

254 DTI quantifies the Brownian motion of water molecules in tissues and organs, which is sensitive
255 in detecting the integrity and direction of fiber bundles[35]. Considered to be the most useful
256 parameter of DTI, FA reflects the integrity of myelin sheaths as well as the number, size, and density
257 of fibers. Pathological process impairing the microstructure of the CNS (such as inflammation,
258 demyelination, or axonal degeneration) will alter the anisotropy of water diffusion and thus the FA.
259 CST transmit output signals of superficial neurons and ultimately projects to the spinal cord anterior
260 horn cells to regulate basic motor functions[36]. As the most common motor neuron disease,
261 amyotrophic lateral sclerosis (ALS), there have been extensive studies showing that the FA of the
262 CST was reduced and correlates with functional scores as well as progression in ALS patients[37-
263 39]. In the current study, we confirmed a causal link between decreased DTI parameters on FA in
264 CST and KOA risk. Although the underlying mechanisms are unknown, these indicators may
265 provide new perspectives for the screening of KOA susceptibility in the future.

266 On the other hand, the current findings suggest that KOA in turn may also lead to an increment
267 of thickness or intensity-contrast in the cingulate, insula, and pallidum. Reduced gray matter volume

268 or density often corresponds to neuronal degeneration or death, as manifested in patients with
269 cerebral hypoxia or infarction[40, 41], and conversely we believe it may be related to neural
270 sensitization. Peripheral and central sensitization has been demonstrated in patients with OA, which
271 leads to local nociceptive sensitization as manifested by decreased pain thresholds[42]. Our results
272 are consistent with a previous pain fMRI meta-analysis study indicating that patients with chronic
273 pain, or experimental pain caused by nociceptive hypersensitivity, showed stronger activation in
274 these brain regions[43]. Moreover, the cingulate and insula are important component of the limbic
275 system, which has a key role in coordinating injurious, cognitive-emotional pain processing[44, 45].
276 It has also been established that depression or low mood triggered by chronic pain contribute to
277 central pain exacerbation and severity[46, 47]. Our findings may provide new explanations for
278 nociceptive hypersensitivity of chronic pain in KOA patients.

279 This study is not without limitations. First, the study used GWAS summary data, which may
280 not allow for stratified analysis of relevant risk factors such as gender, age, obesity, and OA severity.
281 Second, the data of exposure and outcome were obtained only from European populations, which
282 limits the cross-ethnic extrapolation of our findings. Third, as the function of many brain regions is
283 not yet fully understood, which constrained the interpretation of our MR results. In conclusion, this
284 study demonstrated a bidirectional causal relationship between BIDPs and KOA risk. Further
285 studies are needed to confirm and further explore these findings.

286

287 **Author contribution Statement**

288 S.-S.Z. and H.-T.L. designed this study. Z.R. and S.-H.L. wrote the manuscript. S.-S.Z., Z.R. and S.-H.L.

289 analyzed the data and prepared all the figures. C.P., T.-T.X., and L.M. provided technical support. H.-

290 T.L., and S.-S.Z. provided financial support.

291

292 **Ethics approval**

293 All analyses were based on publicly shared databases, and no additional ethical approvals were

294 required.

295

296 **Conflict of Interest Statement**

297 No conflict of interest declared.

298

299 **Funding**

300 This work was financially supported by the National Natural Science Foundation of China (Nos.

301 81902222, and Nos.82060395).

302

303 **Data Availability Statement**

304 All the data are available if qualified authors apply for them.

305 References

- 306 1. O'Neill TW, McCabe PS, McBeth J: **Update on the epidemiology, risk factors and disease**
307 **outcomes of osteoarthritis.**
- 308 2. **Global, regional, and national incidence, prevalence, and years lived with disability for**
309 **354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic**
310 **analysis for the Global Burden of Disease Study 2017.**
- 311 3. Katz JN, Arant KR, Loeser RF: **Diagnosis and Treatment of Hip and Knee Osteoarthritis:**
312 **A Review.**
- 313 4. Sharma A, Kudesia P, Shi Q, Gandhi R: **Anxiety and depression in patients with**
314 **osteoarthritis: impact and management challenges.**
- 315 5. Zhang FA-O, Rao S, Baranova A: **Shared genetic liability between major depressive**
316 **disorder and osteoarthritis.**
- 317 6. Culibrk RA, Hahn MS: **The Role of Chronic Inflammatory Bone and Joint Disorders in the**
318 **Pathogenesis and Progression of Alzheimer's Disease.**
- 319 7. Innes KE, Sambamoorthi U: **The Association of Osteoarthritis and Related Pain Burden to**
320 **Incident Alzheimer's Disease and Related Dementias: A Retrospective Cohort Study of**
321 **U.S. Medicare Beneficiaries.**
- 322 8. Feng SH, Chuang HJ, Yeh KC, Pan SA-O: **Association of Osteoarthritis With Increased Risk**
323 **of Parkinson's Disease: A Population-Based, Longitudinal Follow-Up Study.**
- 324 9. Al-Khazraji BK, Appleton CT, Beier F, Birmingham TB, Shoemaker JK: **Osteoarthritis,**
325 **cerebrovascular dysfunction and the common denominator of inflammation: a narrative**
326 **review.**
- 327 10. Filippi M, Agosta F Fau - Abrahams S, Abrahams S Fau - Fazekas F, Fazekas F Fau -
328 Grosskreutz J, Grosskreutz J Fau - Kalra S, Kalra S Fau - Kassubek J, Kassubek J Fau - Silani
329 V, Silani V Fau - Turner MR, Turner Mr Fau - Masdeu JC, Masdeu JC: **EFNS guidelines on**
330 **the use of neuroimaging in the management of motor neuron diseases.**
- 331 11. Mori S, Zhang J: **Principles of diffusion tensor imaging and its applications to basic**
332 **neuroscience research.** *Neuron* 2006, **51**:527-539.
- 333 12. Frisoni GB, Fox Nc Fau - Jack CR, Jr., Jack Cr Jr Fau - Scheltens P, Scheltens P Fau - Thompson
334 PM, Thompson PM: **The clinical use of structural MRI in Alzheimer disease.**
- 335 13. He M, Shen Z, Ping L, Zhou C, Cheng Y, Xu X: **Age-related heterogeneity revealed by**
336 **disruption of white matter structural networks in patients with first-episode untreated**
337 **major depressive disorder: WM Network In OA-MDD.**
- 338 14. Emdin CA, Khera AV, Kathiresan S: **Mendelian Randomization.**
- 339 15. Funk-Brentano TA-O, Nethander M, Movérare-Skrtic S, Richette PA-O, Ohlsson CA-O:
340 **Causal Factors for Knee, Hip, and Hand Osteoarthritis: A Mendelian Randomization**
341 **Study in the UK Biobank.**
- 342 16. Meng H, Jiang LA-O, Song Z, Wang FA-O: **Causal Associations of Circulating Lipids with**
343 **Osteoarthritis: A Bidirectional Mendelian Randomization Study.** **LID -**
344 **10.3390/nu14071327 [doi] LID - 1327.**
- 345 17. Lin L, Luo P, Yang M, Wang J, Hou W, Xu P: **Causal relationship between osteoporosis and**
346 **osteoarthritis: A two-sample Mendelian randomized study.**
- 347 18. Zeggini E, Panoutsopoulou K, Southam L, Rayner NW, Day-Williams AG, Lopes MC, Boraska

- 348 V, Esko T, Evangelou E, Hoffman A, et al: **Identification of new susceptibility loci for**
349 **osteoarthritis (arcOGEN): a genome-wide association study.** *Lancet* 2012, **380**:815-823.
- 350 19. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL,
351 Neale BM: **LD Score regression distinguishes confounding from polygenicity in genome-**
352 **wide association studies.** *Nat Genet* 2015, **47**:291-295.
- 353 20. Cai Y, Zhang G, Liang J, Jing Z, Zhang R, Lv L, Dang X: **Causal Relationships Between**
354 **Osteoarthritis and Senile Central Nerve System Dysfunction: A Bidirectional Two-Sample**
355 **Mendelian Randomization Study.**
- 356 21. Knutson KA, Deng Y, Pan W: **Implicating causal brain imaging endophenotypes in**
357 **Alzheimer's disease using multivariable IWAS and GWAS summary data.**
- 358 22. Willoughby WR, Thoenes K, Bolding M: **Somatotopic Arrangement of the Human Primary**
359 **Somatosensory Cortex Derived From Functional Magnetic Resonance Imaging.**
- 360 23. Woolsey Cn Fau - Erickson TC, Erickson Tc Fau - Gilson WE, Gilson WE: **Localization in**
361 **somatic sensory and motor areas of human cerebral cortex as determined by direct**
362 **recording of evoked potentials and electrical stimulation.**
- 363 24. Neogi T: **The epidemiology and impact of pain in osteoarthritis.**
- 364 25. Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, Gitelman DR: **Chronic**
365 **back pain is associated with decreased prefrontal and thalamic gray matter density.** *J*
366 *Neurosci* 2004, **24**:10410-10415.
- 367 26. Buckalew N, Haut MW, Morrow L, Weiner D: **Chronic pain is associated with brain volume**
368 **loss in older adults: preliminary evidence.** *Pain Med* 2008, **9**:240-248.
- 369 27. Schmidt-Wilcke T, Leinisch E, Gänssbauer S, Draganski B, Bogdahn U, Altmeyen J, May A:
370 **Affective components and intensity of pain correlate with structural differences in gray**
371 **matter in chronic back pain patients.** *Pain* 2006, **125**:89-97.
- 372 28. Liao X, Mao C, Wang Y, Zhang Q, Cao D, Seminowicz DA, Zhang M, Yang X: **Brain gray**
373 **matter alterations in Chinese patients with chronic knee osteoarthritis pain based on**
374 **voxel-based morphometry.** *Medicine (Baltimore)* 2018, **97**:e0145.
- 375 29. Strotzer M: **One century of brain mapping using Brodmann areas.** *Klin Neuroradiol* 2009,
376 **19**:179-186.
- 377 30. Floresco SB: **The nucleus accumbens: an interface between cognition, emotion, and action.**
378 *Annu Rev Psychol* 2015, **66**:25-52.
- 379 31. Salgado S, Kaplitt MG: **The Nucleus Accumbens: A Comprehensive Review.** *Stereotact*
380 *Funct Neurosurg* 2015, **93**:75-93.
- 381 32. Chang PC, Pollema-Mays SL, Centeno MV, Procissi D, Contini M, Baria AT, Martina M,
382 Apkarian AV: **Role of nucleus accumbens in neuropathic pain: linked multi-scale evidence**
383 **in the rat transitioning to neuropathic pain.** *Pain* 2014, **155**:1128-1139.
- 384 33. Goffer Y, Xu D, Eberle SE, D'Amour J, Lee M, Tukey D, Froemke RC, Ziff EB, Wang J:
385 **Calcium-permeable AMPA receptors in the nucleus accumbens regulate depression-like**
386 **behaviors in the chronic neuropathic pain state.** *J Neurosci* 2013, **33**:19034-19044.
- 387 34. Mallory GW, Abulseoud O, Hwang SC, Gorman DA, Stead SM, Klassen BT, Sandroni P,
388 Watson JC, Lee KH: **The nucleus accumbens as a potential target for central poststroke**
389 **pain.** *Mayo Clin Proc* 2012, **87**:1025-1031.
- 390 35. Martin AR, Aleksanderek I, Cohen-Adad J, Tarmohamed Z, Tetreault L, Smith N, Cadotte DW,
391 Crawley A, Ginsberg H, Mikulis DJ, Fehlings MG: **Translating state-of-the-art spinal cord**

- 392 **MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT,**
393 **MWF, MRS, and fMRI.** *Neuroimage Clin* 2016, **10**:192-238.
- 394 36. Welniarz Q, Dusart I, Roze E: **The corticospinal tract: Evolution, development, and human**
395 **disorders.** *Dev Neurobiol* 2017, **77**:810-829.
- 396 37. Du XQ, Zou TX, Huang NX, Zou ZY, Xue YJ, Chen HJ: **Brain white matter abnormalities**
397 **and correlation with severity in amyotrophic lateral sclerosis: An atlas-based diffusion**
398 **tensor imaging study.** *J Neurol Sci* 2019, **405**:116438.
- 399 38. Ellis CM, Simmons A, Jones DK, Bland J, Dawson JM, Horsfield MA, Williams SC, Leigh PN:
400 **Diffusion tensor MRI assesses corticospinal tract damage in ALS.** *Neurology* 1999,
401 **53**:1051-1058.
- 402 39. Roskopf J, Müller HP, Dreyhaupt J, Gorges M, Ludolph AC, Kassubek J: **Ex post facto**
403 **assessment of diffusion tensor imaging metrics from different MRI protocols: preparing**
404 **for multicentre studies in ALS.** *Amyotroph Lateral Scler Frontotemporal Degener* 2015,
405 **16**:92-101.
- 406 40. Joo EY, Jeon S, Kim ST, Lee JM, Hong SB: **Localized cortical thinning in patients with**
407 **obstructive sleep apnea syndrome.** *Sleep* 2013, **36**:1153-1162.
- 408 41. Yu W, Yang J, Liu L, Song W, Zhang Z, Xu M, Cao Z: **The value of diffusion weighted**
409 **imaging in predicting the clinical progression of perforator artery cerebral infarction.**
410 *Neuroimage Clin* 2022, **35**:103117.
- 411 42. Suokas AK, Walsh DA, McWilliams DF, Condon L, Moreton B, Wylde V, Arendt-Nielsen L,
412 Zhang W: **Quantitative sensory testing in painful osteoarthritis: a systematic review and**
413 **meta-analysis.** *Osteoarthritis Cartilage* 2012, **20**:1075-1085.
- 414 43. Tanasescu R, Cottam WJ, Condon L, Tench CR, Auer DP: **Functional reorganisation in**
415 **chronic pain and neural correlates of pain sensitisation: A coordinate based meta-analysis**
416 **of 266 cutaneous pain fMRI studies.** *Neurosci Biobehav Rev* 2016, **68**:120-133.
- 417 44. Starr CJ, Sawaki L, Wittenberg GF, Burdette JH, Oshiro Y, Quevedo AS, McHaffie JG, Coghill
418 RC: **The contribution of the putamen to sensory aspects of pain: insights from structural**
419 **connectivity and brain lesions.** *Brain* 2011, **134**:1987-2004.
- 420 45. Segerdahl AR, Mezue M, Okell TW, Farrar JT, Tracey I: **The dorsal posterior insula**
421 **subserves a fundamental role in human pain.** *Nat Neurosci* 2015, **18**:499-500.
- 422 46. Villemure C, Bushnell MC: **Mood influences supraspinal pain processing separately from**
423 **attention.** *J Neurosci* 2009, **29**:705-715.
- 424 47. Piñerua-Shuhaibar L, Villalobos N, Delgado N, Rubio MA, Suarez-Roca H: **Enhanced central**
425 **thermal nociception in mildly depressed nonpatients and transiently sad healthy subjects.**
426 *J Pain* 2011, **12**:360-369.
- 427

Table 1. The results of Forward MR (BIDPs were used as exposures).

Exposure BIDPs ID	Outcome	IDP short name	KOA vs Control					
			N (SNPs)	β	SE	P value	OR	Method
7	Knee OA (arcOGEN)	IDP_T1_SIENAX_white_normalised_volume	16	0.335593198	0.162237867	0.038590616	1.398769887	IVW
8	Knee OA (arcOGEN)	IDP_T1_SIENAX_white_unnormalised_volume	15	0.364103774	0.172827997	0.035140062	1.439223561	IVW
24	Knee OA (arcOGEN)	IDP_T1_FIRST_right_accumbens_volume	4	0.687650204	0.314952856	0.029010539	1.989036208	IVW
126	Knee OA (arcOGEN)	IDP_T1_FAST_ROIs_L_putamen	18	0.225852679	0.086885759	0.009338113	1.253391001	IVW
127	Knee OA (arcOGEN)	IDP_T1_FAST_ROIs_R_putamen	16	0.195681385	0.089810251	0.029344203	1.216139363	IVW
144	Knee OA (arcOGEN)	IDP_T1_FAST_ROIs_L_cerebellum_crus_I	21	0.29906601	0.118375693	0.01152336	1.348598641	IVW
146	Knee OA (arcOGEN)	IDP_T1_FAST_ROIs_R_cerebellum_crus_I	13	0.298411367	0.140955296	0.034254426	1.34771608	IVW
181	Knee OA (arcOGEN)	aseg_global_volume_Optic-Chiasm	4	0.726762749	0.296972732	0.014395602	2.068373912	IVW
201	Knee OA (arcOGEN)	aseg_lh_volume_Accumbens-area	9	0.489288172	0.242267012	0.043422446	1.631154705	IVW
272	Knee OA (arcOGEN)	HippSubfield_rh_volume_presubiculum-body	5	0.576319605	0.236674376	0.014888747	1.779477185	IVW
277	Knee OA (arcOGEN)	HippSubfield_rh_volume_CA3-body	6	0.518745785	0.230132289	0.024188622	1.679919348	IVW
289	Knee OA (arcOGEN)	ThalamNuclei_lh_volume_Pul	3	0.517937664	0.237806723	0.029407721	1.678562318	IVW
448	Knee OA (arcOGEN)	aparc-DKTatlas_lh_volume_lingual	6	0.63249724	0.207642094	0.002318357	1.882305283	IVW
547	Knee OA (arcOGEN)	aparc-a2009s_lh_volume_S-circular-insula-inf	3	-1.017220792	0.427168845	0.017251259	0.361598502	IVW
664	Knee OA (arcOGEN)	aparc-Desikan_lh_area_paracentral	3	0.744386864	0.331556352	0.024759836	2.105150295	IVW
711	Knee OA (arcOGEN)	aparc-Desikan_rh_area_superiortemporal	3	-0.631373884	0.312334496	0.043231443	0.531860584	IVW
786	Knee OA (arcOGEN)	BA-exvivo_lh_area_BA4a	4	0.727435725	0.333183684	0.029014655	2.069766347	IVW
824	Knee OA (arcOGEN)	aparc-DKTatlas_lh_area_paracentral	3	0.739780786	0.333685688	0.026623171	2.095476105	IVW
967	Knee OA (arcOGEN)	aparc-a2009s_rh_area_G-oc-temp-med-Lingual	9	0.421148192	0.188918775	0.025796919	1.523710063	IVW
1028	Knee OA (arcOGEN)	aparc-Desikan_lh_thickness_inferiortemporal	4	-0.695018214	0.276983682	0.012099164	0.499065358	IVW
1029	Knee OA (arcOGEN)	aparc-Desikan_lh_thickness_isthmuscingulate	3	-0.752642108	0.310066749	0.015209361	0.471120157	IVW
1084	Knee OA (arcOGEN)	aparc-Desikan_rh_thickness_supramarginal	4	-0.587562051	0.280617622	0.036276252	0.555680355	IVW
1099	Knee OA (arcOGEN)	BA-exvivo_lh_thickness_MT	4	-0.683857342	0.288409946	0.017733815	0.504666562	IVW
1214	Knee OA (arcOGEN)	aparc-a2009s_lh_thickness_G-temporal-inf	4	-0.640463217	0.283699208	0.023974154	0.52704823	IVW
1327	Knee OA (arcOGEN)	aseg_global_intensity_4th-Ventricle	5	-0.554646703	0.232468154	0.017037197	0.574275115	IVW
1349	Knee OA (arcOGEN)	aseg_lh_intensity_Accumbens-area	18	-0.182872874	0.09163022	0.04595893	0.832874029	IVW

1362	Knee OA (arcOGEN)	aseg_rh_intensity_Amygdala	3	-0.603116447	0.302801552	0.046394342	0.547103956	IVW
1363	Knee OA (arcOGEN)	aseg_rh_intensity_Accumbens-area	18	-0.186169809	0.086901398	0.032168475	0.830132619	IVW
1371	Knee OA (arcOGEN)	wg_lh_intensity-contrast_cuneus	18	0.225734307	0.113240385	0.046216772	1.253242643	IVW
1406	Knee OA (arcOGEN)	wg_rh_intensity-contrast_cuneus	22	0.280719327	0.10646927	0.008373584	1.324081918	IVW
1439	Knee OA (arcOGEN)	IDP_SWI_T2star_right_thalamus	5	-0.466016192	0.222154767	0.035930805	0.627497124	IVW
1491	Knee OA (arcOGEN)	IDP_dMRI_TBSS_FA_Fornix_cres+Stria_terminalis_L	8	0.710499467	0.297056239	0.016765921	2.035007423	IVW
1603	Knee OA (arcOGEN)	IDP_dMRI_TBSS_MD_Pontine_crossing_tract	4	-1.038511303	0.332764364	0.001803232	0.353981261	IVW
1651	Knee OA (arcOGEN)	IDP_dMRI_TBSS_L1_Pontine_crossing_tract	8	-0.86702052	0.219996619	8.11213E-05	0.420201668	IVW
1667	Knee OA (arcOGEN)	IDP_dMRI_TBSS_L1_Anterior_limb_of_internal_capsule_L	10	-0.471261642	0.186928873	0.011699703	0.624214237	IVW
1696	Knee OA (arcOGEN)	IDP_dMRI_TBSS_L1_Tapetum_R	3	-0.730049887	0.322082217	0.023411192	0.48188495	IVW
1704	Knee OA (arcOGEN)	IDP_dMRI_TBSS_L2_Corticospinal_tract_R	7	-0.525102523	0.25581608	0.04010591	0.59149472	IVW
1705	Knee OA (arcOGEN)	IDP_dMRI_TBSS_L2_Corticospinal_tract_L	7	-0.808443389	0.264859886	0.00227062	0.445551076	IVW
1747	Knee OA (arcOGEN)	IDP_dMRI_TBSS_L3_Pontine_crossing_tract	3	-1.100943965	0.385352012	0.004276894	0.332557013	IVW
1844	Knee OA (arcOGEN)	IDP_dMRI_ProbtrackX_L1_str_l	7	-0.37913881	0.185718772	0.041204395	0.684450597	IVW
1845	Knee OA (arcOGEN)	IDP_dMRI_ProbtrackX_L1_str_r	6	-0.484829751	0.239481298	0.042918791	0.615802027	IVW
1861	Knee OA (arcOGEN)	IDP_dMRI_ProbtrackX_L2_ifo_r	13	-0.291854609	0.132295676	0.027378524	0.746877117	IVW
1918	Knee OA (arcOGEN)	IDP_dMRI_TBSS_ICVF_Anterior_limb_of_internal_capsule_R	15	0.283740719	0.136324102	0.037400171	1.328088538	IVW
2053	Knee OA (arcOGEN)	IDP_dMRI_TBSS_ISOVF_Pontine_crossing_tract	4	-0.897098021	0.418801426	0.032188608	0.40775123	IVW
2059	Knee OA (arcOGEN)	IDP_dMRI_TBSS_ISOVF_Corticospinal_tract_L	4	-1.077645475	0.332915164	0.001207946	0.340396054	IVW
2069	Knee OA (arcOGEN)	IDP_dMRI_TBSS_ISOVF_Anterior_limb_of_internal_capsule_L	7	0.575327735	0.202738305	0.004542776	1.777713049	IVW
2093	Knee OA (arcOGEN)	IDP_dMRI_TBSS_ISOVF_Superior_longitudinal_fasciculus_L	8	0.374959486	0.18062504	0.037903219	1.454932468	IVW
2114	Knee OA (arcOGEN)	IDP_dMRI_ProbtrackX_ISOVF_ilf_l	10	0.30959031	0.141694168	0.02889477	1.362866647	IVW
2122	Knee OA (arcOGEN)	IDP_dMRI_ProbtrackX_ISOVF_slf_r	18	0.288203364	0.114741868	0.012013275	1.33402857	IVW
2124	Knee OA (arcOGEN)	IDP_dMRI_ProbtrackX_ISOVF_str_r	7	0.499842719	0.229576992	0.02946315	1.648461979	IVW

BIDPs: Brain imaging-derived phenotypes; SE: standard error; N(SNPs): Number of SNPs; IVW, inverse variance weighted.

Table 2. The results of Reverse MR (BIDPs were used as outcomes).

Exposre	Outcome BIDPs ID	IDP short name	KOA vs Control					
			N (SNPs)	β	SE	P value	OR	Method
Knee OA (arcOGEN)	18	IDP_T1_FIRST_right_pallidum_volume	4	0.0807	0.0355	0.02283319	1.084071738	IVW
Knee OA (arcOGEN)	48	IDP_T1_FAST_ROIs_L_mid_temp_gyrus_post	4	-0.0681	0.0291	0.01914813	0.934167893	IVW
Knee OA (arcOGEN)	54	IDP_T1_FAST_ROIs_L_inf_temp_gyrus_post	4	-0.0644	0.0291	0.02670215	0.937616755	IVW
Knee OA (arcOGEN)	70	IDP_T1_FAST_ROIs_L_latocc_cortex_inf	4	-0.0680	0.0330	0.03922326	0.934306506	IVW
Knee OA (arcOGEN)	94	IDP_T1_FAST_ROIs_L parahipp_gyrus_post	4	-0.0573	0.0291	0.04864192	0.944294832	IVW
Knee OA (arcOGEN)	100	IDP_T1_FAST_ROIs_L_temp_fusif_cortex_post	4	-0.0651	0.0291	0.02518339	0.936997495	IVW
Knee OA (arcOGEN)	120	IDP_T1_FAST_ROIs_L_occ_pole	4	0.0573	0.0291	0.0485507	1.059016069	IVW
Knee OA (arcOGEN)	128	IDP_T1_FAST_ROIs_L_pallidum	4	0.1003	0.0301	0.000843084	1.105519765	IVW
Knee OA (arcOGEN)	129	IDP_T1_FAST_ROIs_R_pallidum	4	0.0795	0.0291	0.006267096	1.082702077	IVW
Knee OA (arcOGEN)	185	aseg_global_volume_CC-Mid-Anterior	4	-0.0645	0.0296	0.02933929	0.937491629	IVW
Knee OA (arcOGEN)	387	aparc-Desikan_rh_volume_lateralorbitofrontal	4	0.0635	0.0315	0.04388895	1.065567989	IVW
Knee OA (arcOGEN)	555	aparc-a2009s_lh_volume_S-intrapariet+P-trans	4	0.0585	0.0296	0.0483287	1.06023644	IVW
Knee OA (arcOGEN)	625	aparc-a2009s_rh_volume_S-front-inf	4	-0.0700	0.0296	0.01813876	0.932398762	IVW
Knee OA (arcOGEN)	663	aparc-Desikan_lh_area parahippocampal	4	-0.0852	0.0296	0.004024795	0.918324844	IVW
Knee OA (arcOGEN)	731	aparc-pial_lh_area parahippocampal	4	-0.0892	0.0296	0.00260549	0.91467058	IVW
Knee OA (arcOGEN)	794	BA-exvivo_lh_area_perirhinal	4	-0.0586	0.0296	0.04777777	0.94304927	IVW
Knee OA (arcOGEN)	823	aparc-DKTatlas_lh_area parahippocampal	4	-0.0856	0.0296	0.003860497	0.917967942	IVW
Knee OA (arcOGEN)	884	aparc-a2009s_lh_area_G-front-inf-Orbital	4	0.0631	0.0296	0.03326742	1.06509774	IVW
Knee OA (arcOGEN)	894	aparc-a2009s_lh_area_G-oc-temp-med-Parahip	4	-0.0621	0.0296	0.03618754	0.93982923	IVW
Knee OA (arcOGEN)	897	aparc-a2009s_lh_area_G-pariet-inf-Supramar	4	-0.0677	0.0296	0.022264	0.934526458	IVW
Knee OA (arcOGEN)	917	aparc-a2009s_lh_area_S-cingul-Marginalis	4	0.0673	0.0296	0.0231901	1.069567969	IVW
Knee OA (arcOGEN)	1045	aparc-Desikan_lh_thickness_rostralanteriorcingulate	4	0.0597	0.0296	0.04393311	1.061501961	IVW
Knee OA (arcOGEN)	1057	aparc-Desikan_rh_thickness_caudalmiddlefrontal	4	-0.0702	0.0296	0.01783849	0.932228577	IVW
Knee OA (arcOGEN)	1148	aparc-DKTatlas_rh_thickness_caudalmiddlefrontal	4	-0.0736	0.0296	0.01299452	0.929059077	IVW
Knee OA (arcOGEN)	1306	aparc-a2009s_rh_thickness_S-interm-prim-Jensen	4	-0.0629	0.0296	0.03377106	0.939046801	IVW

Knee OA (arcOGEN)	1369	wg_lh_intensity-contrast_caudalanteriorcingulate	4	0.0709	0.0296	0.0166977	1.073473852	IVW
Knee OA (arcOGEN)	1392	wg_lh_intensity-contrast_rostralanteriorcingulate	4	0.1038	0.0296	0.000459863	1.109349492	IVW
Knee OA (arcOGEN)	1404	wg_rh_intensity-contrast_caudalanteriorcingulate	4	0.0753	0.0296	0.011108	1.078154766	IVW
Knee OA (arcOGEN)	1436	wg_rh_intensity-contrast_insula	4	0.0715	0.0296	0.01574411	1.074156369	IVW
Knee OA (arcOGEN)	1504	IDP_dMRI_ProbtrackX_FA_cgc_l	4	-0.0704	0.0299	0.0186896	0.932053046	IVW
Knee OA (arcOGEN)	1508	IDP_dMRI_ProbtrackX_FA_cst_l	4	-0.0646	0.0299	0.0308279	0.9374333	IVW
Knee OA (arcOGEN)	1538	IDP_dMRI_TBSS_MO_Inferior_cerebellar_peduncle_L	4	0.0690	0.0299	0.0210732	1.071457049	IVW
Knee OA (arcOGEN)	1551	IDP_dMRI_TBSS_MO_Superior_corona_radiata_R	4	-0.0756	0.0299	0.01155813	0.927222306	IVW
Knee OA (arcOGEN)	1552	IDP_dMRI_TBSS_MO_Superior_corona_radiata_L	4	-0.0718	0.0299	0.01642042	0.930722233	IVW
Knee OA (arcOGEN)	1723	IDP_dMRI_TBSS_L2_Superior_corona_radiata_L	4	0.0705	0.0299	0.01838723	1.073094253	IVW
Knee OA (arcOGEN)	1879	IDP_dMRI_ProbtrackX_L3_cgc_l	4	0.0794	0.0375	0.03446909	1.082627189	IVW
Knee OA (arcOGEN)	2001	IDP_dMRI_TBSS_OD_Superior_corona_radiata_R	4	0.0653	0.0299	0.0289965	1.067518184	IVW
Knee OA (arcOGEN)	2002	IDP_dMRI_TBSS_OD_Superior_corona_radiata_L	4	0.0715	0.0299	0.01689801	1.07409916	IVW
Knee OA (arcOGEN)	2060	IDP_dMRI_TBSS_ISOVF_Medial_lemniscus_R	4	-0.0639	0.0299	0.03268759	0.938088298	IVW
Knee OA (arcOGEN)	2061	IDP_dMRI_TBSS_ISOVF_Medial_lemniscus_L	4	-0.0626	0.0299	0.0364241	0.939316581	IVW
Knee OA (arcOGEN)	2125	IDP_dMRI_ProbtrackX_ISOVF_unc_l	4	0.0639	0.0299	0.0327	1.0660	IVW

BIDPs: Brain imaging-derived phenotypes; SE: standard error; N(SNPs): Number of SNPs; IVW, inverse variance weighted.